Pharmacometrics: Focus on the Patient

Pharmacometrics, whether using simple or complex models, has contributed to rational and efficient drug development,(1–3) with the main focus on early drug development.(4) This article describes why opportunities more directly focused on the patient abound in late stage development, illustrating the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumitrescu, T Pene, Fossler, MJ, Schmith, VD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369753/
https://www.ncbi.nlm.nih.gov/pubmed/26225220
http://dx.doi.org/10.1002/psp4.5
_version_ 1782362788172136448
author Dumitrescu, T Pene
Fossler, MJ
Schmith, VD
author_facet Dumitrescu, T Pene
Fossler, MJ
Schmith, VD
author_sort Dumitrescu, T Pene
collection PubMed
description Pharmacometrics, whether using simple or complex models, has contributed to rational and efficient drug development,(1–3) with the main focus on early drug development.(4) This article describes why opportunities more directly focused on the patient abound in late stage development, illustrating the concept with three innovative examples which focus on benefits to patients, enabling drugs that are truly efficacious to reach the market faster in diseases with high unmet medical needs, while maintaining adequate safety.
format Online
Article
Text
id pubmed-4369753
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43697532015-03-23 Pharmacometrics: Focus on the Patient Dumitrescu, T Pene Fossler, MJ Schmith, VD CPT Pharmacometrics Syst Pharmacol Perspectives Pharmacometrics, whether using simple or complex models, has contributed to rational and efficient drug development,(1–3) with the main focus on early drug development.(4) This article describes why opportunities more directly focused on the patient abound in late stage development, illustrating the concept with three innovative examples which focus on benefits to patients, enabling drugs that are truly efficacious to reach the market faster in diseases with high unmet medical needs, while maintaining adequate safety. BlackWell Publishing Ltd 2015-01 2014-12-30 /pmc/articles/PMC4369753/ /pubmed/26225220 http://dx.doi.org/10.1002/psp4.5 Text en © 2014 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Perspectives
Dumitrescu, T Pene
Fossler, MJ
Schmith, VD
Pharmacometrics: Focus on the Patient
title Pharmacometrics: Focus on the Patient
title_full Pharmacometrics: Focus on the Patient
title_fullStr Pharmacometrics: Focus on the Patient
title_full_unstemmed Pharmacometrics: Focus on the Patient
title_short Pharmacometrics: Focus on the Patient
title_sort pharmacometrics: focus on the patient
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369753/
https://www.ncbi.nlm.nih.gov/pubmed/26225220
http://dx.doi.org/10.1002/psp4.5
work_keys_str_mv AT dumitrescutpene pharmacometricsfocusonthepatient
AT fosslermj pharmacometricsfocusonthepatient
AT schmithvd pharmacometricsfocusonthepatient

Ejemplares similares